Search

Your search keyword '"Ohtsuki, Mamitaro"' showing total 819 results

Search Constraints

Start Over You searched for: Author "Ohtsuki, Mamitaro" Remove constraint Author: "Ohtsuki, Mamitaro"
819 results on '"Ohtsuki, Mamitaro"'

Search Results

1. Biomarkers and patient-related factors associated with clinical outcomes in dupilumab-treated atopic dermatitis

4. Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up

9. Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials.

10. Expert consensus on systemic therapy for plaque psoriasis with limited skin involvement in JAPAN: Results from a DELPHI study.

12. Interleukin‐33 Deficiency Protects the Skin From Ulcer Formation in an Ischemia–Reperfusion‐Induced Decubitus Mouse Model.

15. Deucravacitinib in Plaque Psoriasis: 3-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1 and PSO-2 Trials

18. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open‐label, phase 3 trial

20. Overexpression of the β-Subunit of Acid Ceramidase in the Epidermis of Mice Provokes Atopic Dermatitis-like Skin Symptoms.

21. Exploring patient background and biomarkers associated with the development of dupilumab-associated conjunctivitis and blepharitis

23. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

26. Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials

27. The ability of biomarkers to assess the severity of atopic dermatitis

30. Exploring patient background and biomarkers associated with the development of dupilumab-associated conjunctivitis and blepharitis

31. Exploration of biomarkers to predict clinical improvement of atopic dermatitis in patients treated with dupilumab: A study protocol

34. TLR7/8 stress response drives histiocytosis in SLC29A3 disorders

37. The ability of biomarkers to assess the severity of atopic dermatitis

44. Diagnostic clues for pagetoid Bowen's disease

48. Exploring biomarkers to predict clinical improvement of atopic dermatitis in patients treated with dupilumab (B‐PAD study)

Catalog

Books, media, physical & digital resources